IBUPROFEN 400MG, 600MG, 800MG TABLETS NATIONAL CONTRACT
ID: SPE2D220R0057P00009Type: Special Notice
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

PSC

DRUGS AND BIOLOGICALS (6505)
Timeline
    Description

    Special Notice DEPT OF DEFENSE is seeking IBUPROFEN 400MG, 600MG, 800MG TABLETS. This medication is typically used for pain relief, reducing inflammation, and lowering fever. The notice is from the DEFENSE LOGISTICS AGENCY, DLA TROOP SUPPORT. The primary contact for this procurement is Denise Taubman (denise.taubman@dla.mil, 2157376877) and the secondary contact is Catherine Gilbert (catherine.gilbert@dla.mil, 2157374778). The notice includes AMENDMENT 00009 to incorporate telecommunication clauses into the solicitation.

    Point(s) of Contact
    Files
    Title
    Posted
    Lifecycle
    Title
    Type
    Similar Opportunities
    Ibuprofen 400MG/ 600MG/ 800MG Presolicitation
    Dept Of Defense
    Presolicitation notice from the Department of Defense, Defense Logistics Agency, DLA Troop Support, for a national requirements contract for Ibuprofen Tablets. The contract will establish a national supply source to provide Ibuprofen 400MG in 30, 90, and 500 count bottles, as well as Ibuprofen 600MG and 800MG in 90 and 500 count bottles. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items will be purchased by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. Interested parties should contact Kevin Rafferty for more information. The projected solicitation date is April 2021.
    Ibuprofen 400MG/600MG/800MG Tablets
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Ibuprofen 400MG/600MG/800MG Tablets. The contract will establish a national supply source to provide the items for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is March of 2023.
    Telmisartan Tablets
    Dept Of Defense
    The Defense Logistics Agency (DLA) is soliciting proposals for the procurement of Telmisartan Tablets, a pharmaceutical product, to be delivered over multiple contract years. This solicitation, identified as SPE2D2-24-R-0015, requires compliance with various federal regulations, including the submission of a Subcontracting Plan for large businesses and adherence to Federal Acquisition Regulation (FAR) clauses concerning ethics and subcontracting practices. Telmisartan is crucial for managing hypertension and ensuring a reliable pharmaceutical supply is vital for military personnel's health. Interested vendors should submit their electronic proposals via the Defense Logistics Agency Internet Bid Board System (DIBBS) and can contact Courtney Hunter-Stangler at 215-737-6845 or via email at Courtney.Hunter-Stangler@dla.mil for further information.
    Oxycodone HCL Acetaminophen 325MG National Contract Solitiation
    Dept Of Defense
    Special Notice DEPT OF DEFENSE is seeking Oxycodone HCL Acetaminophen 325MG through a national contract solicitation. Oxycodone HCL Acetaminophen 325MG is a medication used for pain relief. The place of performance for this procurement is Weatherby, MO (zip code: 63119), USA. For more information, contact Denise Taubman at denise.taubman@dla.mil or 215-737-6877.
    Dimethyl Fumarate DR Presolicitation
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    SPE2D220R0063 BUPROPION XL AMENDMENT 0002
    Dept Of Defense
    Special Notice DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is seeking BUPROPION XL. This procurement is for drugs and biologicals under PSC code 6505. The primary contact for this procurement is Catherine Gilbert (catherine.gilbert@dla.mil, 2157374778) and the secondary contact is Denise Taubman (denise.taubman@dla.mil, 2157376877). The notice includes Amendment 0002, which incorporates telecommunication clauses. The solicitation is not reopened and the closing date is not extended. BUPROPION XL is typically used for medical purposes.
    Bicalutamide 50MG tablets
    Dept Of Defense
    The Defense Logistics Agency (DLA) is issuing a solicitation for a national requirements contract for Bicalutamide 50MG tablets, available in bottle counts of 30 and 500. The procurement aims to establish a reliable supply source for these pharmaceutical items, which are critical for various Department of Defense and other federal health programs, including the Department of Veterans Affairs and the Indian Health Service. This unrestricted and fully competitive acquisition will be a firm-fixed price contract with a one-year base and four one-year options, with proposals due by January 24, 2025. Interested parties can reach out to Keith Ryales at keith.ryales@dla.mil or 215-737-9199 for further inquiries and are encouraged to monitor the DLA Bid Board System and SAM.gov for updates on the solicitation.
    Lansoprazole Capsules
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Lansoprazole capsules, specifically 30MG in 100 count bottles. This procurement aims to establish a national supply source for the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons, ensuring a reliable supply of this essential pharmaceutical item. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options, with the solicitation expected to be posted in April 2024. Interested parties should direct inquiries to Jeremy Brown at jeremy.brown@dla.mil or 215-737-6031, and are encouraged to set up automated notifications for updates on the solicitation through the DLA Bid Board System and Sam.Gov.
    Pantoprazole DR Tablets
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE Pantoprazole DR Tablets: The Defense Logistics Agency is planning to issue a national requirements contract for Pantoprazole DR Tablets. These tablets, available in 20MG and 40MG strengths, will be provided in 90 and 1000 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The tablets will be purchased by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the solicitation. Interested parties can find more information on the DLA Bid Board System and Beta Sam.Gov websites. The solicitation is projected to be issued in September 2021.
    Rabeprazole Sodium Delayed Release Tablets
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. The tablets will be used for medical purposes and will be available in 30, 90, and 500 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source to provide the tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should contact Phyllis Daraio for more information. The projected solicitation date is February 2020.